Shell M&A Chief Exits After BP Takeover Proposal Rejected 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
PHOENIX, Feb. 03, 2016 -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “Company”) today announced that the Company will release its financial results for the fourth quarter and full year 2015 on Tuesday, February 23, 2016, before the U.S. financial markets open.
Following the release of the financial results, Dr. John N. Kapoor, President and Chief Executive Officer, and Darryl S. Baker, Chief Financial Officer, will host a conference call at 10:00 a.m. Eastern Standard Time.
Interested parties may participate in the conference call by dialing (877) 349-4844 (U.S.) or (262) 558-6141 (International), 5-10 minutes prior to the start of the call. A replay will be available shortly after the completion of the call for one week by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (International) and entering conference call ID number 43995357.
A live audio webcast and archive of the call will also be available at www.insysrx.com.
About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets one product, Subsys® (fentanyl sublingual spray). The Company recently submitted a New Drug Application to the U.S. Food and Drug Administration for Syndros® (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is developing a pipeline of sublingual sprays, as well as pharmaceutical cannabidiol.
Subsys® and Syndros® are registered trademarks of Insys Therapeutics, Inc.
Contact: Lisa M. Wilson President In-Site Communications, Inc. 212-452-2793
